Wnt/β-catenin信号通路在多发性骨髓瘤中的机制研究进展

doi:10.11958/20220179

天津医药 ›› 2022, Vol. 50 ›› Issue (8): 888-891.doi: 10.11958/20220179

Wnt/β-catenin信号通路在多发性骨髓瘤中的机制研究进展

许家威¹(), 郭一慧¹, 宋辉¹, 程纬民²^,^Δ()

1广西中医药大学（邮编530200）
2广西中医药大学第一附属医院血液内科

收稿日期:2022-01-30 修回日期:2022-03-30 出版日期:2022-08-15 发布日期:2022-08-12
通讯作者: 程纬民 E-mail:yjzyxujiawei@163.com;cheng5min@126.com
作者简介:许家威（1997）,男,硕士在读,主要从事血液肿瘤中西医结合临床方面研究。E-mail： yjzyxujiawei@163.com
基金资助:
国家自然科学基金地区科学基金项目(81960839);广西研究生教育创新计划项目(YCSW2021224)

The research progress on the mechanism of Wnt/β-catenin signaling pathway involved in multiple myeloma

XU Jiawei¹(), GUO Yihui¹, SONG Hui¹, CHENG Weimin²^,^Δ()

1 Guangxi University of Chinese Medicine, Nanning 530200, China
2 Department of Hematology, the First Affiliated Hospital of Guangxi University of Chinese Medicine

Received:2022-01-30 Revised:2022-03-30 Published:2022-08-15 Online:2022-08-12
Contact: CHENG Weimin E-mail:yjzyxujiawei@163.com;cheng5min@126.com

许家威, 郭一慧, 宋辉, 程纬民. Wnt/β-catenin信号通路在多发性骨髓瘤中的机制研究进展[J]. 天津医药, 2022, 50(8): 888-891.

XU Jiawei, GUO Yihui, SONG Hui, CHENG Weimin. The research progress on the mechanism of Wnt/β-catenin signaling pathway involved in multiple myeloma[J]. Tianjin Medical Journal, 2022, 50(8): 888-891.

摘要/Abstract

摘要：

多发性骨髓瘤（MM）是一种以骨髓浆细胞恶性增殖为特征的血液肿瘤,其发生机制与相关的信号通路异常有着密切关系。Wnt/β-catenin信号通路可参与调节细胞的增殖、分化和凋亡等生物学过程,且与细胞癌变相关。在MM中,异常表达的非编码RNAs、转录因子、蛋白酶和分泌蛋白等可激活Wnt/β-catenin信号通路,进而加速MM的发生和发展。因此,Wnt/β-catenin信号通路在MM的发病机制中具有重要地位。整理总结MM中相关非编码RNAs、转录因子、蛋白酶和分泌蛋白等影响Wnt/β-catenin信号通路的研究进展,以期为相关研究提供参考。

关键词: 多发性骨髓瘤, 生物标记,肿瘤, Wnt信号通路, β连环素

Abstract:

Multiple myeloma (MM) is a hematological tumor characterized by malignant proliferation of bone marrow plasma cells, and its mechanism of occurrence is closely related to the abnormalities of related signaling pathways. Wnt/β-catenin signaling pathway is involved in the regulation of cell proliferation, differentiation, apoptosis and other biological processes, and it is associated with cell carcinomatosis. In MM, abnormally expressed non-coding RNAs, transcription factors, proteases and secreted proteins can activate the Wnt/β-catenin signaling pathway, thus accelerating the occurrence and development of MM. Therefore, Wnt/β-catenin signaling pathway plays an important role in the pathogenesis of MM. This paper collates and summarizes the research progress of relevant non-coding RNAs, transcription factors, proteases and secretory proteins in MM that affect the Wnt/β-catenin signaling pathway, in order to provide reference for related research.

Key words: multiple myeloma, biomarkers, tumor, Wnt signaling pathway, beta catenin

中图分类号:

R733.3

参考文献 29

[1]	VAN D E, DONK N W C J, PAWLYN C, et al. Multiple myeloma[J]. Lancet, 2021, 397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
[2]	YUAN Y, GUO M, GU C, et al. The role of Wnt/β-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma(review)[J]. Am J Transl Res, 2021, 13(9):9932-9949.
[3]	ANDEL H, KOCEMBA K A, SPAARGAREN M, et al. Aberrant Wnt signaling in multiple myeloma:molecular mechanisms and targeting options[J]. Leukemia, 2019, 33(5):1063-1075. doi: 10.1073/pnas.1618650114.
[4]	DAI Y, GUO X, YANG C. Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β-catenin signaling pathway[J]. Oncol Lett, 2020, 20(2):1295-1299. doi: 10.3892/ol.2020.11678.
[5]	LYBRAND D, BNAIMAN M, LAUMANN J M, et al. Destruction complex dynamics:Wnt/β-catenin signaling alters Axin-GSK3β interactions in vivo[J/OL]. Development, 2019, 146(13):dev164145. doi: 10.1242/dev.164145.
[6]	QI J, LEE H J, SAQUET A, et al. Autoinhibition of dishevelled protein regulated by its extreme C terminus plays a distinct role in Wnt/β-catenin and Wnt/planar cell polarity(PCP) signaling pathways[J]. J Biol Chem, 2017, 292(14):5898-5908. doi: 10.1074/jbc.M116.772509.
[7]	GUO B, XIAO C, LIU Y, et al. MiR-744-5p inhibits multiple myeloma proliferation,epithelial mesenchymal transformation and glycolysis by targeting SOX12/Wnt/β-Catenin signaling[J]. Onco Targets Ther, 2021(14):1161-1172. doi: 10.2147/OTT.S270636.
[8]	LIU Q, RAN R, SONG M, et al. LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β‐catenin/cyclin D1 signaling via PLAGL2[J]. Cell Biol Toxicol, 2021. doi: 10.1007/s10565-021-09628-7. ［Epub ahead of print］.
[9]	ZHOU F, WANG D, ZHOU N, et al. Circular RNA protein tyrosine kinase 2 promotes cell proliferation,migration and suppresses apoptosis via activating microRNA-638 mediated MEK/ERK,Wnt/β-catenin signaling pathways in multiple myeloma[J]. Front Oncol, 2021(11):648189. doi: 10.3389/fonc.2021.648189.
[10]	DESANTIS V, SOLIMANDO A G, SALTARELLA I, et al. MicroRNAs as a potential new preventive approach in the transition from asymptomatic to symptomatic multiple myeloma disease[J]. Cancers(Basel), 2021, 13(15):3650. doi: 10.3390/cancers13153650.
[11]	XIANG P, YEUNG Y T, WANG J, et al. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition[J]. Int J Cancer, 2021, 148(12):3071-3085. doi: 10.1002/ijc.33528.
[12]	王椋, 徐敏, 邢健, 等. MiR-144调控Wnt4/β-catenin信号通路抑制MM细胞恶性生物学行为的研究[J]. 中国实验血液学杂志, 2020, 28(4):1256-1260.
	WANG L, XU M, XING J, et al. MiR-144 inhibits the malignant biologic behaviors of multiple myeloma cells by regulating Wnt4/β-catenin signaling pathway[J]. Journal of Experimental Hematology, 2020, 28(4):1256-1260. doi: 10.19746/j.cnki.issn.1009-2137.2020.04.029.
[13]	GOWDA P S, WILDMAN B J, TROTTER T N, et al. Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression[J]. Mol Cancer Res, 2018, 16(7):1138-1148. doi: 10.1158/1541-7786.
[14]	WU Z, ZHANG Y, YANG Z, et al. Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion[J]. Cancer Cell Int, 2021, 21(1):187. doi: 10.1186/s12935-021-01887-y.
[15]	CHEN H, ZHAO Y, ZHANG J, et al. Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway[J]. Cytokine, 2021, 142:155495. doi: 10.1016/j.cyto.2021.155495.
[16]	ZHOU M, CHEN J, ZHANG H, et al. KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p[J]. Int J Biol Sci, 2020, 16(12):2063-2071. doi: 10.7150/ijbs.45999.
[17]	CUI Y S, SONG Y P, FANG B J. The role of long non-coding RNAs in multiple myeloma[J]. Eur J Haematol, 2019, 103(1):3-9. doi: 10.1111/ejh.13237.
[18]	CHEN R, ZHANG X, WANG C. LncRNA HOXB-AS1 promotes cell growth in multiple myeloma via FUT4 mRNA stability by ELAVL1[J]. J Cell Biochem, 2020, 121(10):4043-4051. doi: 10.1002/jcb.29573.
[19]	GENG W, GUO X, ZHANG L, et al. Resveratrol inhibits proliferation,migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2018, 107:484-494. doi: 10.1016/j.biopha.2018.08.003.
[20]	PEREZ DE ACHA O, ROSSI M, GOROSPE M. Circular RNAs in blood malignancies[J]. Front Mol Biosci, 2020, 7:109. doi: 10.3389/fmolb.2020.00109.
[21]	GAO Y, LI L, HOU L, et al. SOX12 promotes the growth of multiple myeloma cells by enhancing Wnt/β-catenin signaling[J]. Exp Cell Res, 2020, 388(1):111814. doi: 10.1016/j.yexcr.2020.111814.
[22]	LV M, LIU Q. JMJD2C triggers the growth of multiple myeloma cells via activation of β-catenin[J]. Oncol Rep, 2021, 45(3):1162-1170. doi: 10.3892/or.2021.7934.
[23]	VAN ANDEL H, KOCEMBAR K A, DE HAAN-KRAMER A, et al. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease[J]. Oncogene, 2017, 36(15):2105-2115. doi: 10.1038/onc.2016.368.
[24]	REN Z, VAN ANDEL H, DE LAU W, et al. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins[J]. Blood, 2018, 131(9):982-994. doi: 10.1182/blood-2017-07-797050.
[25]	REN Z, SPAARGAREN M, PALS S T. Syndecan-1 and stromal heparan sulfate proteoglycans:key moderators of plasma cell biology and myeloma pathogenesis[J]. Blood, 2021, 137(13):1713-1718. doi: 10.1182/blood.2020008188.
[26]	LIU X, PENG J, ZHOU Y, et al. Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β-catenin signaling pathway[J]. Mol Med Rep, 2019, 20(3):2159-2166. doi: 10.3892/mmr.2019.10465.
[27]	FENG Y, ZHANG Y, WEI X, et al. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma[J]. Cancer Biomark, 2019, 24(2):195-201. doi: 10.3233/CBM-181909.
[28]	COLUCCI S, BRUNETTI G, ORANGER A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion[J]. Blood Cancer J, 2011, 1(6):e27. doi: 10.1038/bcj.2011.22.
[29]	MCDONALD M M, REAGAN M R, YOULTEN S E, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma[J]. Blood, 2017, 129(26):3452-3464. doi: 10.1182/blood-2017-03-773341.

Wnt/β-catenin信号通路在多发性骨髓瘤中的机制研究进展

The research progress on the mechanism of Wnt/β-catenin signaling pathway involved in multiple myeloma

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	方杰, 黄芮, 郑红慧, 贾倩倩, 鲍静. miR-9-5p靶向TIMP2诱导多发性骨髓瘤细胞自噬和凋亡的机制[J]. 天津医药, 2024, 52(8): 785-790.
[2]	王宁方, 赵崇山, 刘方, 赵鹏浩, 张东东, 蔡卓纹, 蔡芳芳. 多发性骨髓瘤患者淋巴细胞来源微泡的检测及其临床意义[J]. 天津医药, 2024, 52(4): 409-415.
[3]	钟家帅, 冯玉梅. 小鼠骨髓和脂肪间充质干细胞定向分化能力的比较研究[J]. 天津医药, 2024, 52(2): 129-135.
[4]	柏宇, 兰雪娇, 唐璟, 文雨, 吕明敏, 宋庆高. 沉默Sp5对mEPMCs中Wnt信号通路相关因子及增殖能力的影响[J]. 天津医药, 2023, 51(12): 1314-1320.
[5]	刘荟敏, 许旋旋, 王远丽, 熊涛, 唐元艳. CircBACH1调节miR-140-5p/MDM2轴对多发性骨髓瘤细胞增殖、凋亡和化疗敏感性的影响[J]. 天津医药, 2023, 51(11): 1170-1175.
[6]	宋玉, 朱争艳, 黄桓, 李春, 鲁晶泉, 刘和宇, 胡丽娜. 虾青素通过调节Klotho表达和Wnt/β-Catenin信号通路对多囊卵巢综合征大鼠的改善作用[J]. 天津医药, 2023, 51(10): 1098-1103.
[7]	刘猛, 姜玖良, 付立跃, 李俊俊, 朱海涛. 多纳非尼抑制胆管癌TFK-1细胞增殖、迁移和侵袭及促进凋亡的机制研究[J]. 天津医药, 2022, 50(12): 1259-1263.
[8]	李振江, 孙德超, 孔晨旭, 耿亚东, 徐晨阳, 丁炳谦. 白藜芦醇通过BRD4调控Wnt/β-catenin通路逆转胶质瘤细胞替莫唑胺耐药的机制研究[J]. 天津医药, 2022, 50(10): 1043-1049.
[9]	阮成群, 肖永杰, 李记天△. Linc00891通过竞争性结合并抑制miR-27a-3p在骨肉瘤中发挥抑癌作用#br#[J]. 天津医药, 2021, 49(5): 449-454.
[10]	付庆华, 夏冰, 杨洪亮, 许雯, 赵海丰, 于泳, 赵智刚, 王亚非, 王晓芳△. 初诊伴髓外病变的多发性骨髓瘤患者的临床特征及预后分析 #br#[J]. 天津医药, 2020, 48(5): 415-420.
[11]	袁涛, 文坤明△. microRNAs在调控结直肠癌肿瘤干细胞相关信号通路中的作用机制[J]. 天津医药, 2020, 48(11): 1115-1119.
[12]	王倩, 黎谢梦丹, 罗凯, 郑国沛, 张志杰, 卢敏莹, 董静, 贾小婷, 贺智敏. Wnt信号通路转录上调EGFR促进非小细胞肺癌吉非替尼耐药[J]. 天津医药, 2020, 48(1): 8-13.
[13]	刘涛 , 宋庆高 . Wnt/β-catenin信号通路调控Sp5机制的研究进展[J]. 天津医药, 2019, 47(5): 556-560.
[14]	董倩倩, 吴玮玮, 张锡友, 陈峰, 李丹丹. 嵌合抗原受体T细胞在多发性骨髓瘤治疗中的研究进展[J]. 天津医药, 2018, 46(10): 1127-1131.
[15]	方梓青 1，黄幸儒 1，陈旭 1，李志远 2，李振杰 3，张建国 1，方坚 4△. 补肾养骨汤诱导多发性骨髓瘤细胞株 KM3 的凋亡及机制探讨[J]. 天津医药, 2018, 46(1): 7-11.